Online inquiry

IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10176MR)

This product GTTS-WQ10176MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Myocardial infarction research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10176MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1552MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ7673MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ11202MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ7858MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ11367MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ7861MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ2074MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ12410MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW